Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s share price traded up 11.9% on Tuesday . The stock traded as high as $3.74 and last traded at $3.68, with a volume of 276,251 shares changing hands. The stock had previously closed at $3.29.

Several equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 25th. Chardan Capital lowered their target price on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating on the stock in a report on Monday, August 15th. Cowen and Company reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Friday, August 5th. Leerink Swann reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. Finally, Stifel Nicolaus lowered their target price on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating on the stock in a report on Thursday, June 30th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Dicerna Pharmaceuticals has a consensus rating of “Buy” and an average target price of $11.85.

The firm has a 50 day moving average of $3.33 and a 200 day moving average of $3.96. The firm’s market cap is $80.94 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/dicerna-pharmaceuticals-inc-drna-trading-11-9-higher.html

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.09. On average, equities analysts forecast that Dicerna Pharmaceuticals Inc. will post ($3.17) EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Oxford Asset Management boosted its stake in shares of Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth approximately $343,000. Paloma Partners Management Co purchased a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth approximately $183,000. A.R.T. Advisors LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth approximately $170,000. Finally, RTW Investments LLC boosted its stake in shares of Dicerna Pharmaceuticals by 2.6% in the first quarter. RTW Investments LLC now owns 2,026,894 shares of the biopharmaceutical company’s stock worth $10,864,000 after buying an additional 51,665 shares during the last quarter. 62.38% of the stock is currently owned by institutional investors and hedge funds.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.